Lexicon Pharmaceuticals Q3 2026 net loss widens 9% to $14 million
LXRX•Lexicon Pharmaceuticals’ third-quarter 2026 net loss widened 9% year over year to $14 million, while revenue fell 20% to $11.3 million. The company expects top-line results from its 542-patient SONATA-HCM trial and a ZYNQUISTA NDA resubmission in the first quarter of 2027.
1. Quarterly results and trials
Lexicon Pharmaceuticals’ third-quarter net loss widened 9% year over year to $14 million, and total revenue fell 20% to $11.3 million, including $10 million in Novo development milestone revenue. Research and development expenses declined 14% to $16.2 million, reflecting lower external research expenses. The Phase 3 SONATA-HCM trial completed enrollment with 542 patients, with top-line results expected in the first quarter of 2027; a ZYNQUISTA NDA resubmission is also anticipated in that quarter, supported by positive STENO1 safety data.
